Tandem Diabetes Care (TNDM) Gross Profit Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 5.02% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 8.10% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 4.54% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 15.44% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 9.03% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 3.15% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 17.49% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 1.49% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 8.46% |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn | 18.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.16% |
| Dec 31, 2025 | 13.17% |
| Sep 30, 2025 | 8.75% |
| Jun 30, 2025 | 7.28% |
| Mar 31, 2025 | 9.14% |
| Dec 31, 2024 | 11.45% |
| Sep 30, 2024 | 8.82% |
| Jun 30, 2024 | 6.85% |
| Mar 31, 2024 | 8.91% |
| Dec 31, 2023 | 1.00% |
| Sep 30, 2023 | 11.18% |
| Jun 30, 2023 | 23.21% |
| Mar 31, 2023 | 18.16% |
| Dec 31, 2022 | 24.22% |
| Sep 30, 2022 | 27.25% |
| Jun 30, 2022 | 26.89% |
| Mar 31, 2022 | 39.78% |
| Dec 31, 2021 | 39.90% |
| Sep 30, 2021 | 64.34% |
| Jun 30, 2021 | 83.00% |
| Mar 31, 2021 | 85.92% |
| Dec 31, 2020 | 73.07% |
| Sep 30, 2020 | 76.53% |
| Jun 30, 2020 | 89.43% |
| Mar 31, 2020 | 95.24% |
| Dec 31, 2019 | 81.59% |
| Sep 30, 2019 | 224.40% |
| Jun 30, 2019 | 82.75% |
| Mar 31, 2019 | 68.86% |
| Dec 31, 2018 | 45.59% |
| Sep 30, 2018 | 58.12% |
| Jun 30, 2018 | 46.47% |
| Mar 31, 2018 | 59.55% |
| Dec 31, 2017 | 38.77% |
| Sep 30, 2017 | 39.26% |
| Jun 30, 2017 | 32.39% |
| Mar 31, 2017 | 98.23% |
| Dec 31, 2016 | 103.86% |
| Sep 30, 2016 | -37.90% |
| Jun 30, 2016 | 172.06% |
| Mar 31, 2016 | 50.30% |